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ABSTRACT
Mutation in one of three RAS genes (i.e., HRAS, KRAS, and NRAS) leading to 
constitutive activation of RAS signaling pathways is considered a key oncogenic 
event in human carcinogenesis. Whether activated RAS isoforms possess different 
oncogenic potentials remains an unresolved question. Here, we compared 
oncogenic properties among RAS isoforms using liver-specific transgenesis in mice. 
Hydrodynamic transfection was performed using transposons expressing short hairpin 
RNA downregulating p53 and an activated RAS isoform, and livers were harvested 
at 23 days after gene delivery. No differences were found in the hepatocarcinogenic 
potential among RAS isoforms, as determined by both gross examination of livers and 
liver weight per body weight ratio (LW/BW) of mice expressing HRASQ61L, KRAS4BG12V 
and NRASQ61K. However, the tumorigenic potential differed significantly between KRAS 
splicing variants. The LW/BW ratio in KRAS4AG12V mice was significantly lower than 
in KRAS4BG12V mice (p < 0.001), and KRAS4AG12V mice lived significantly longer than 
KRRAS4BG12V mice (p < 0.0001). Notably, tumors from KRAS4AG12V mice displayed 
higher expression of the p16INK4A tumor suppressor when compared with KRAS4BG12V 
tumors. Forced overexpression of p16INK4A significantly reduced tumor growth in 
KRAS4BG12V mice, suggesting that upregulation of p16INK4A by KRAS4AG12V presumably 
delays tumor development driven by the latter oncogene.
INTRODUCTION
RAS proteins are small 21-kDa GTPases that 
activate a variety of key cellular processes including 
growth, proliferation, and migration [1–3]. In humans, 
three RAS genes encode four highly homologous RAS 
proteins: HRAS, NRAS, KRAS4A and KRAS4B, with 
the latter two resulting from alternative splicing of 
exon 4 of the KRAS gene [4–6]. All RAS isoforms are 
expressed almost ubiquitously and interact with the same 
activator and effector molecules, suggesting that they are 
functionally redundant [7–10]. However, it was proposed 
that the highly variable carboxyl-terminal of 25 amino 
acid residues might provide the isoforms with different 
biological functions [6, 10–12]. For example, Millan et al. 
reported that HRAS exhibited a stronger activation of NF-
κB signaling than KRAS and NRAS in NIH3T3 cells, thus 
rendering them more resistant to staurosporine-induced 
apoptosis [13].
Activating mutations in RAS genes have been 
identified in approximately 15 - 30% of human cancers 
[3, 4]. These mutations, resulting in unrestrained RAS 
activity, lead to the sustained activation of diverse 
signaling pathways involved in carcinogenesis [2]. 
Cancer mutation databases (e.g., the COSMIC database; 
http://cancer.sanger.ac.uk/cosmic) show that mutation 
frequencies are highly biased among RAS genes in a 
given type of cancer [4, 9, 14]. For example, activating 
mutations in the KRAS gene prevail in lung, colon 
and pancreatic cancers, while mutations in NRAS and 
HRAS are rarely found in these cancer types. Likewise, 
activating mutations in NRAS are predominantly found 
in hematopoietic malignancies, where mutations in 
HRAS are rarely detected. Mutations in HRAS occur 
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preferentially in tumors of the skin and salivary glands. 
In liver cancer, activating mutations in KRAS and NRAS 
are found considerably more frequently than in HRAS [4, 
9, 14]. Based on the biased mutation frequencies observed 
among the RAS genes in different types of cancer, it was 
suggested that an intrinsic difference in the tumorigenic 
potential among the RAS isoforms might occur for a given 
type of cancer. In support of this hypothesis, Haigis et al. 
showed that a constitutively active form of KRAS is more 
tumorigenic than that of NRAS in mouse models of colon 
cancer, possibly explaining why mutations in KRAS are 
more frequently observed than NRAS in human colon 
tumors [15]. However, the apparent biases in mutation 
frequencies among the RAS genes in human cancers could 
be caused by factors other than differential oncogenic 
characteristics of RAS isoforms, such as differences 
in expression levels or mutation rates due to different 
genomic locations among the RAS genes [16, 17].
Here, we compared the tumorigenic potential of 
the four RAS isoforms in the liver using non-germline 
transgenic mouse models. The methodology employs a 
hydrodynamics-based transfection method, coupled with the 
Sleeping Beauty (SB) transposon system, which has been 
successfully used to generate various transgenic models 
for liver cancer [18, 19]. An open reading frame (ORF) 
encoding an activated form of each RAS isoform was 
placed under the same promoter and regulatory elements 
in the same transposon vectors to rule out differential 
regulation of transcription and translation. Further, 
transposons are randomly integrated in a chromosome of 
each cell, thus minimizing the locus effect [20].
RESULTS
Generation of transgenic models expressing 
constitutively active RAS isoforms
To investigate whether there is any difference 
in the hepatocarcinogenic potential among activated 
RAS isoforms, we developed transgenic mouse models 
expressing activated human RAS isoforms in the liver. 
For this purpose, we employed hydrodynamic transfection 
(HT) coupled with the Sleeping Beauty (SB) transposon 
system [18, 19].
First, we tested the differential hepatocarcinogenic 
potential among RAS isoforms carrying the same 
activating mutation (i.e., encoding valine instead of 
glycine at codon 12). For this purpose, we constructed 
transposons encoding HRASG12V, KRAS4AG12V, 
KRAS4BG12V, and NRASG12V by placing the open 
reading frame (ORF) for each activated RAS isoform 
into transposon-based expression vectors (Figure 1A). 
Isoform-specific RAS expression of the constructed 
transposons was confirmed by Western blotting using 
whole protein extracts from Hep3B cells transfected with 
individual transposons. Notably, Western blotting revealed 
that the phosphorylation levels of major downstream 
effectors of RAS pathways—such as AKT, MEK and 
ERK—were similar among cells expressing each RAS 
isoform (Figure 1B). Compared to cells transfected with 
transposons encoding enhanced green fluorescent protein 
(EGFP), elevated levels of the phosphorylated proteins 
characterized all RAS-transfected cells (Figure 1B). The 
results suggest that RAS proteins expressed from the 
transposons were equally functional.
Activated RAS alone cannot induce tumors in the 
liver, while concomitant p53 knockdown using a short 
hairpin RNA (shp53) efficiently induces liver cancer 
[21]. Thus, transposons encoding each activated RAS 
isoform and transposons expressing shp53 were co-
delivered to the liver via hydrodynamic injection along 
with plasmids expressing SB transposase (Figure 2A). 
Livers were harvested at 23 days post-hydrodynamic 
injection (PHI). Numerous tumor nodules were found in 
livers from HRASG12V, KRAS4BG12V, and NRASG12V mice. 
Tumor burden was most severe in KRAS4BG12V mice with 
tumor lesions occupying most of the liver parenchyma 
(Figure 2B). Much fewer and smaller nodules were 
detected in livers from KRAS4AG12V mice compared to 
mice expressing other RAS isoforms. No tumors were 
detected in control livers expressing EGFP (Figure 
2B) as well as in livers injected only with transposons 
encoding activated RAS (data not shown). Consistent 
with macroscopic observation, ratios of liver weight/
body weight (LW/BW) were highest in KRAS4BG12V 
mice and lowest in KRAS4AG12V mice, in the order of 
KRAS4BG12V > NRASG12V ≈ HRASG12V > KRAS4AG12V ≈ 
EGFP (Figure 2C).
Equivalent hepatocarcinogenic potential of 
activated HRAS, KRAS4B and NRAS genes
Activating mutations can also arise in RAS genes 
at codons 13 and 61. In particular, activating mutations 
at codon 61 occur more frequently than at codon 12 of 
HRAS and NRAS in most cancer types, in contrast to 
KRAS where a mutation at codon 12 is predominant [14]. 
To investigate whether the tumorigenic potential can be 
enhanced by shifting the position of an activating mutation 
to codon 61 in HRAS and NRAS, transposons encoding 
HRASQ61L and NRASQ61K were used to induce liver 
tumors. When livers were harvested at 23 days PHI, no 
differences were detected in tumor burden among livers 
expressing KRAS4BG12V, HRASQ61L and NRASQ61K (Figure 
3A). Consistently, no differences were seen in LW/BW 
ratios among the three groups (Figure 3B). This strongly 
indicates that the intrinsic oncogenic potential does not 
differ among HRAS, NRAS and KRAS proto-oncogenes 
and that the codon positions of an activating mutation in 
RAS can affect the oncogenic potential of a given type of 
RAS isoform. Although activating mutations in HRAS 
are observed considerably less frequently in liver cancer 
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Figure 1: Transposons encoding each form of activated RAS. A. Schematic illustration of transposons encoding activated RAS 
isoforms. Transposons encoding enhanced green fluorescent protein (EGFP) were used as a negative control. B. Expression of RAS and 
activation of downstream effector molecules were confirmed in Hep3B hepatoma cells transfected with the indicated transposons. Two 
days after transfection, Western blotting was performed using whole proteins extracted from cells. K4A and K4B indicate KRAS4AG12V 
and KRAS4BG12V, respectively.
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Figure 2: Expression of an activated RAS isoform and shp53 in the liver via hydrodynamic transfection. A. Schematic 
illustration of the experimental procedure to generate transgenic livers expressing an activated form of RAS (RAS*) and short hairpin RNA 
downregulating p53 (shp53). Hydrodynamic transfection was performed using a mixture of the indicated plasmids. B. Gross morphology of 
representative livers harvested at 23 days post-hydrodynamic injection from mice expressing each RAS isoform with the same activating mutation 
at codon 12 resulting in the substitution of valine for glycine. Liver expressing EGFP is shown as a control. C. Liver weight/body weight (LW/
BW) ratios of mice expressing the indicated RAS isoforms. Mice expressing HRASG12V, KRAS4BG12V and NRASG12V had significantly higher 
LW/BW ratios compared to control mice expressing EGFP. Note that the LW/BW ratio of KRAS4AG12V mice is similar to that of EGFP mice. 
The graph represents mean LW/BW ± SD. Single, double and triple asterisks indicate p < 0.05, p < 0.01 and p < 0.001, respectively.
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Figure 3: Expression of RAS isoforms with different types of activating mutations. A. Gross morphology of representative 
livers harvested from mice expressing each form of activated RAS at 23 days post-hydrodynamic injection. The amino acid substitutions 
at codon 61 in HRAS and NRAS (resulting in HRASQ61L and NRASQ61K, respectively) rendered HRAS and NRAS as oncogenic as 
KRAS4BG12V. Livers expressing KRAS4BG12D had similar tumor burdens as those expressing KRAS4BG12V. Note that tumors were fewer 
and smaller in livers expressing KRAS4AG12D compared to those in KRAS4BG12D livers. B. Liver weight/body weight (LW/BW) ratios of 
mice expressing the indicated RAS isoforms. Note that LW/BW ratios differed significantly between KRAS4A and other RAS isoforms. 
The graph represents mean LW/BW ± SD. C. Kaplan–Meier survival curves of mice expressing KRAS4AG12V and KRAS4BG12V following 
hydrodynamic transfection. Differences in survival were highly significant (P < 0.0001).
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compared to NRAS or KRAS [4, 9, 14], our data show that 
activated HRAS has an oncogenic potential equal to that 
of NRAS or KRAS counterparts in the liver, calling for 
further research to explain the biased mutation frequencies 
among the RAS isoforms found in human cancers.
Another interesting question regarding mutations in 
RAS is whether activating mutations at the same codon 
position that result in different amino acid substitutions 
endow RAS with different oncogenic characteristics. 
Previous studies using knock-in mouse models showed 
that KRASG12D induced hyperplasia in tissues more 
efficiently than KRASG12V, raising the possibility that 
KRASG12D and KRASG12V might have different oncogenic 
potentials [22, 23]. To address this question, transposons 
encoding KRASG12D and KRASG12V were used for 
hydrodynamic transfection. When livers were harvested 
and grossly examined at 23 days PHI, KRASG12D and 
KRASG12V livers showed no significant differences in 
tumor burden (Figure 3A). The LW/BW ratios confirmed 
this finding (Figure 3B). Thus, we speculate that the 
substitution of valine and aspartic acid at codon 12 has a 
similar effect on the oncogenic potential of KRAS, at least 
in the mouse liver.
Activated KRAS4A is less oncogenic than 
activated KRAS4B in the liver
To test whether the differences in tumor growth 
between KRAS4AG12V and KRAS4BG12V livers can also 
be seen in another frequently found mutation in the 
KRAS gene, a hydrodynamic injection experiment was 
performed using transposons encoding KRAS4AG12D and 
KRAS4BG12D. As found in KRAS4AG12V and KRAS4BG12V 
mice, KRAS4AG12D mice had fewer and smaller tumors 
in the liver than KRAS4BG12D mice at 23 days after 
hydrodynamic injection (Figure 3A). The LW/BW ratio 
of KRAS4AG12D mice was almost identical to that of 
EGFP mice, and about four folds smaller than that of 
KRAS4BG12D mice (p < 0.01; see Figure 3B).
The results suggest that KRAS4A is less oncogenic 
than KRAS4B in the liver, irrespective of the type of 
activating mutation. In addition, the present data suggest 
that the KRAS4B splicing variant is the major driver of 
hepatocarcinogenesis when an activating mutation occurs 
in the KRAS gene. In accordance with these findings, 
it has been reported that the KRAS4A/4B transcript 
ratio is significantly reduced in colorectal tumors when 
compared with that in corresponding non-tumor tissues, 
further suggesting that activated KRAS4B might be more 
oncogenic than activated KRAS4A in cancer [24, 25].
To evaluate the effect of reduced tumor growth in 
KRAS4AG12V livers on the survival of mice, we compared 
the survival of KRAS4AG12V mice (n=17) and KRAS4BG12V 
(n=15) mice following hydrodynamic transfection. 
The survival analysis showed that KRAS4AG12V mice 
survived significantly longer than KRAS4BG12V mice 
(p < 10−4), suggesting that reduced tumor development in 
KRAS4AG12V livers prolonged their life span (Figure 3C).
Reduced cellular proliferation in KRAS4AG12V 
tumors
Histopathologic examination showed that tumors 
from both KRAS4AG12V and KRAS4BG12V groups were 
poorly differentiated HCC. There were no phenotypic 
differences in tumor cells between the two groups (Figure 4). 
Tumor cells revealed an almost identical morphology 
of highly atypical nuclei. Immunohistochemical (IHC) 
analysis with antibodies against GFP confirmed that the 
tumors in both groups originated from cells transfected with 
the transposons (Figure 4).
To characterize the reduced tumor growth in 
KRAS4AG12V mice at the cellular level, cell proliferation 
and apoptosis were investigated in the tumor. Proliferation 
of tumor cells was significantly reduced in KRAS4AG12V 
compared to KRAS4BG12V, as determined by Ki-67 
staining (Figure 4). Apoptotic cells were rarely detected 
in tumor sections from both groups using terminal 
deoxynucleotidyltransferase-mediated dUTP-biotin 
nick-end labeling (TUNEL) staining (Figure 4). Thus, 
the decreased level of cellular proliferation is likely 
responsible for the slower growth of tumors expressing 
KRAS4AG12V.
Upregulation of p16INK4A in tumors of 
KRAS4AG12V
To characterize the reduced cellular proliferation in 
KRAS4AG12V tumors at the molecular level, some players 
in RAS-dependent growth were compared between 
KRAS4AG12V and KRAS4BG12V tumors via Western 
blotting. Whole proteins were extracted from KRAS4BG12V 
tumors at 23 days PHI and used for immunoblotting. 
Because nodules were too small in KRAS4AG12V livers at 
23 days PHI, whole protein extracts from KRAS4AG12V 
tumors at 37 days PHI were used instead for this study. 
Western blotting showed that expression levels of RAS 
were similar between KRAS4AG12V and KRAS4BG12V 
tumors (Figure 5). Major downstream effector molecules 
of RAS signaling pathways were also similarly activated 
in both groups, as determined by phosphorylation levels of 
AKT, MEK, and ERK (Figure 5). Thus, the reduced tumor 
growth of KRAS4AG12V tumors does not depend on low 
level of the transgene expression or insufficient activation 
of the PI3K-AKT and RAF-MEK-ERK downstream 
pathways by the activated KRAS protein.
Because reduced cellular proliferation was observed 
in KRAS4AG12V mice, expression levels of genes involved 
in cell cycle regulation were assessed. We were particularly 
interested in cyclin-dependent kinase inhibitors (CDKIs) 
suppressing cell cycle progression because RAS can 
activate various CDKIs, such as p16INK4A and p21Cip1 
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[26, 27]. Western blotting revealed that the level of p16INK4A 
was significantly higher in KRAS4AG12V tumors compared 
to KRAS4BG12V tumors, while p21Cip1 and P27Kip1 expression 
did not differ between KRAS4AG12V and KRAS4BG12V 
malignant lesions (Figure 5). To investigate whether 
upregulation of p16INK4A can suppress KRAS-driven 
tumorigenesis, transposons were constructed in which 
p16INK4A was co-expressed with KRAS4BG12V (Figure 6A). 
Compared to the control gene encoding firefly luciferase, 
overexpression of p16INK4A significantly suppressed 
hepatocarcinogenesis induced by KRAS4BG12V (Figure 6A). 
Although further analysis is required to elucidate the 
underlying molecular mechanism, the findings suggest that 
an activated KRAS4A potentiates upregulation of p16INK4A, 
which, in turn, functions as a critical tumor suppressor in 
KRAS4A-driven hepatocarcinogenesis [28].
Upregulated p16INK4A can induce senescence in cells 
expressing an activated RAS in vitro and in vivo, known 
Figure 4: Histological analysis of tumors expressing KRAS4AG12V and KRAS4BG12V. Paraffin sections of KRAS4AG12V and 
KRAS4BG12V tumors, as well as liver parenchyma from EGFP mice, were stained with H&E, anti-GFP and anti-Ki-67 antibodies and 
TUNEL reagents. Scale bar: 100 μm for H&E and GFP staining and 50 μm for Ki-67 and TUNEL staining.
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as oncogene-induced senescence (OIS) [26, 29, 30]. To 
investigate whether senescence was involved in p16INK4A-
mediated tumor suppression in KRAS4AG12V tumors, 
Western blotting was performed using antibodies against 
heterochromatin protein 1 gamma (HP1γ) and decoy 
receptor 2 (DCR2), molecular markers for senescence 
[31]. Although the expression level of HP1γ was higher 
in KRAS4AG12V tumors than in KRAS4BG12V tumors, no 
difference was seen in DCR2 levels between the two 
groups (Figure 5). Further, a senescence-associated β-gal 
assay showed no staining difference in KRAS4AG12V and 
KRAS4BG12V tumors, suggesting that tumor suppression 
in KRAS4AG12V tumors by upregulated p16INK4A is not 
mediated by cellular senescence (Figure 6B).
Since oncogenic mutations in KRAS are 
predominantly found in human lung, pancreatic and 
colorectal tumors, it would be intriguing to assess 
whether KRAS4A and 4B would display a differential 
carcinogenic potential in those tissues as well. However, 
the in vivo evaluation of KRAS4A and KRAS4B 
oncogenic potential in extrahepatic tissues is not as 
simple as in the liver due to the lack of an efficient and 
simple method for tissue-specific transgenesis such as 
hydrodynamic transfection. As an alternative approach, 
we investigated the oncogenic potential of KRAS4A and 
4B using the SW48 human colorectal cancer cell line, 
which harbors no mutation in RAS genes [32]. SW48 
cells stably expressing KRAS4BG12V grew significantly 
Figure 5: Expression levels of various genes and phosphorylation levels of RAS downstream effector molecules. 
Tumors were harvested from mice and whole proteins were extracted from each tumor. Protein extracts from livers transfected with 
EGFP were used as controls. Expression levels of the indicated genes and phosphorylation levels of the indicated proteins were assessed 
by immunoblotting using the appropriate antibodies. Note that the expression level of P16INK4A, a cyclin-dependent kinase inhibitor, was 
significantly upregulated in KRAS4AG12V tumors compared to KRAS4BG12V tumors.
Oncotarget7362www.impactjournals.com/oncotarget
faster than those expressing KRAS4AG12V (Figure 7A), 
suggesting that KRAS4B is likely more oncogenic than 
KRAS4A in colorectal tissue. A higher expression of 
p16INK4A was observed in colorectal cancer cells expressing 
KRAS4AG12V, compared to those expressing KRAS4BG12V, 
although both cells exhibited similar levels of KRAS 
(Figure 7B and 7C).
DISCUSSION
In this study, we compared the oncogenic potential 
among activated RAS isoforms in the mouse liver 
and found that no differences in intrinsic oncogenic 
potential among HRAS, KRAS and NRAS exist. One can 
assume differential oncogenic characteristics among 
RAS isoforms from a high frequency of activating 
mutations in a specific RAS gene for a given type of 
cancer [4, 9, 14]. However, other factors could result 
in biased frequencies of activated RAS isoforms in 
cancers, including differences in tissue-specific gene 
expression levels and/or mutation rates among the RAS 
genes due to their different genomic locations. In line 
with our findings, To et al. showed that HRAS located 
at the endogenous genomic location of KRAS underwent 
an activating mutation and induced lung tumors as 
efficiently as KRAS [33].
Figure 6: Overexpression of P16INK4A suppresses tumor growth driven by activated KRAS. A. Transposons were constructed 
that co-express KRAS4BG12V and p16INK4A (or firefly luciferase as a control) in a single open reading frame via 2A-mediated ribosome 
skipping. Hydrodynamic transfection was performed using the indicated plasmids. Gross morphology of representative livers is shown 
below. B. Frozen sections of KRAS4AG12V and KRAS4BG12V tumors were assayed using senescence-associated β-gal staining. No difference 
in β-gal staining level was observed between tumors expressing KRAS4AG12V and KRAS4BG12V.
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Figure 7: Colorectal cancer cells expressing KRAS4BG12V are more proliferative than those expressing KRAS4AG12V. 
A. An MTT assay was performed at the indicated time points using the SW48 human colorectal cancer cell line stably expressing 
KRAS4AG12V and KRAS4BG12V. An asterisk (*) indicates p < 0.05. B. Western blotting was performed using whole proteins extracted from 
the colorectal cancer cells stably expressing KRAS4AG12V and KRAS4BG12V. C. Densitometry analysis of the western blots shown in (B). 
Values represent the relative ratio of p16INK4A/GAPDH in cells expressing KRAS4AG12V and KRAS4BG12V.
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The oncogenic potential differed significantly 
between the two KRAS splicing variants, with KRAS4B 
being more tumorigenic than KRAS4A in the liver. Thus, 
it is presumed that when an activating mutation arises in 
KRAS, KRAS4B will predominantly lead the tumorigenic 
processes. In colorectal cancer, it was reported that the 
KRAS4B isoform is selectively overexpressed and thus, 
the ratio of KRAS4A/4B isoforms is reduced during 
colorectal carcinogenesis, suggesting that KRAS4B might 
be more tumorigenic than KRAS4A [24, 25].
Although the mechanism underlying the reduced 
oncogenicity by KRAS4A was not fully investigated 
in this study, we detected a significant upregulation of 
p16INK4A in KRAS4A-driven liver tumors compared 
to KRAS4B tumors. Ectopic expression of p16INK4A 
led to significantly reduced tumor growth induced by 
activated KRAS4BG12V (Figure 6A), emphasizing the 
tumor-suppressive role of upregulated p16INK4A in KRAS-
driven hepatocarcinogenesis. p16INK4A can prevent cell 
proliferation by inhibiting cell cycle progression. We 
detected a decreased level of cell proliferation in KRAS4A 
tumors compared to KRAS4B tumors, but no differences 
were seen in apoptosis and senescence levels between the 
two tumors (Figures 4 and 6B). Further investigation is 
needed to understand the mechanism whereby activated 
KRAS4A upregulates p16INK4A to a greater degree than 
activated KRAS4B.
MATERIALS AND METHODS
Plasmids
The pT2/shp53/GFP4, pT2/EGFP, and pPGK-SB13 
plasmids were described previously [21].
Human cDNA encoding HRAS, KRAS4B and 
NRAS were used for site-directed mutagenesis to 
generate open reading frames (ORFs) encoding HRASG12V, 
HRASQ61L, KRAS4BG12V, KRAS4BG12D, NRASG12V, and 
NRASQ61K. ORFs encoding KRAS4AG12V and KRAS4AG12D 
were generated from KRAS4BG12V and KRAS4BG12D, 
respectively via PCR using the following primer pairs: 
forward, 5′-ATG ACT GAA TAT AAA CTT GTG GTA 
GTT-3′; and reverse, 5′-TTA CAT TAT AAT GCA TTT 
TTT AAT TTT CAC ACA GCC AGG AGT CTT TTC 
TTC TTT GCT GAT TTT TTT CAA TCT GTA TTG 
TCG GAT CTC CCT CAC CAA TGT ATA AAA AGC 
ATC CTC CAC TCT CTG TCT TGT CTT TGC TGA 
TGT TTC-3′. Each ORF encoding an activated RAS was 
substituted for EGFP cDNA in pT2/EGFP. Transposons 
co-expressing p16INK4A and KRAS4BG12V were generated 
as follows. After removing the termination codon in 
cDNA encoding p16INK4A, the DNA sequence encoding the 
Thosea asigna virus (TaV) 2A peptide with a GSG linker 
at the N-terminus (i.e., GSGEGRGSLLTCGDVEENPGP) 
was placed, in-frame, between cDNA encoding p16INK4A 
and cDNA encoding KRAS4BG12V [34]. Subsequently, the 
fusion DNA was inserted in pT2/EGFP after removing 
EGFP cDNA. Transposons co-expressing firefly luciferase 
and KRAS4BG12V were constructed in the same manner.
Transfection and western blotting
Hep3B cells were transfected with 2μg of plasmid 
DNA using FuGENE HD Transfection Reagent (Promega, 
Madison, WI, USA), according to the manufacturer’s 
instructions. Two days post transfection, cells were lysed 
in 1× RIPA buffer (#9806; Cell Signaling Technology, 
Danvers, MA, USA).Western blot experiments were 
performed using standard methods. Anti-HRAS (sc-520; 
Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
KRAS (sc-30; Santa Cruz Biotechnology), anti-NRAS 
(sc-519; Santa Cruz Biotechnology), anti-AKT (#9272, 
Cell Signaling Technology, Danvers, MA, USA), anti-
phospho-AKT (#4060, Cell Signaling Technology), anti-
MEK (#9126, Cell Signaling Technology), anti-phospho-
MEK (#9154, Cell Signaling Technology), anti-ERK 
(#9102, Cell Signaling Technology), anti-phospho-ERK 
(#4370, Cell Signaling Technology), anti-p16INK4A (10883-
1-AP; Proteintech, Chicago, IL, USA), anti-GAPDH 
(#2118; Cell Signaling Technology), and anti-β-actin (sc-
47778; Santa Cruz Biotechnology) were used as primary 
antibodies, and horseradish peroxidase (HRP)-conjugated 
anti-rabbit IgG (A0545;Sigma-Aldrich, St. Louis, MO, 
USA) was used as the secondary antibody.
Stable cell lines and cell proliferation assay
The human SW48 colorectal cancer cell line 
was transfected with 2μg of pcDNA3- KRAS4AG12V or 
KRAS4BG12V. Two days post transfection, cells were 
placed in culture media containing G418 disulfate salt (G-
8168; Sigma-Aldrich) for the selection of stably expressing 
cells. To evaluate proliferation, colorectal cancer cells 
stably expressing KRAS4AG12V and KRAS4BG12V, 
respectively, were seeded at a density of 1,500 cells 
per well in a 96-well plate. At specified time points, an 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay was performed according to the 
manufacturer’s instructions (Cell Viability, Proliferation 
and Cytotoxicity Assay kit; DOGEN, Seoul, Korea). 
Absorbance at 450 nm was measured using a microplate 
reader (VersaMax ELISA Microplate Reader, Molecular 
Devices, Sunnyvale, CA, USA).
Animal experiments
All experiments using live mice were approved by 
the Animal Policy and Welfare Committee of the Yonsei 
University College of Medicine (Seoul, Korea). Wild-
type C57BL/6 mice were purchased from Orientbio 
(Seongnam, Korea). For hydrodynamic injection, 12.5 μg 
of transposons encoding an activated RAS were mixed 
with 14 μg of pT2/shp53/GFP4 and 9 μg of pPGK-SB13, 
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and then suspended in 2 ml of Lactated Ringer’s solution. 
Each DNA solution was injected into the lateral tail vein 
of 6-week-old C57BL/6 male mice (0.1 ml/g body weight) 
in less than 7 seconds.
Liver harvesting and histopathological analysis
Mice were deeply anesthetized by intraperitoneal 
injection of zoletil (30 mg/kg) and xylazine (10 mg/
kg). A midline laparotomy incision was performed, and 
their livers were removed and fixed overnight in freshly 
prepared 10% neutral-buffered formalin. The remainder 
of the liver was snap-frozen in liquid nitrogen and stored 
at -70°C until use. Fixed tissue samples were embedded 
in paraffin and sectioned into 4-μm slices. Slices were 
stained with hematoxylin & eosin (H&E). Liver lesions 
were assessed by certified pathologists and liver experts 
(S.R. and F.D.) in accordance with the criteria established 
by Frith et al [35].
Immunohistochemistry (IHC) and TUNEL assay
Paraffin sections were deparaffinized in xylene 
and rehydrated through a gradual decrease in ethanol 
concentration. Antigen epitopes were then unmasked using 
sodium citrate buffer (pH 6.0). Subsequently, the sections 
were incubated overnight at 4°C using the following primary 
antibodies: anti-GFP (#2555; Cell Signaling Technology), 
anti-Ki-67 (ab15580; Abcam, Cambridge, UK). After 
primary antibody incubation, sections were incubated with 
a biotinylated anti-rabbit IgG secondary antibody (PK-7200; 
Vector Laboratories, Burlingame, CA, USA) followed by 
treatment with freshly prepared DAB substrates (PK-4100; 
Vector Laboratories). Sections were lightly counter-stained 
with hematoxylin and mounted. Apoptosis was assessed in 
liver sections using terminal deoxynucleotidyl transferase-
mediated dUTP-biotin nick end-labeling (TUNEL) staining 
(ApopTag® In Situ Apoptosis Detection Kits; Merck, 
Billerica, MA, USA). Slides were analyzed and photographed 
using a microscope (Eclipse Ti; Nikon, Tokyo, Japan) 
equipped with a digital camera.
Protein harvest from liver and western blotting
Liver tissues were homogenized and digested in 
1× RIPA buffer containing phosphatase inhibitor cocktail 
solution (GenDEPOT, Barker, TX, USA). Western blot 
experiments were performed following the standard 
protocol. The following primary antibodies were used: 
anti-Pan-RAS (sc-14022; Santa Cruz Biotechnology), 
anti-phospho-AKT (#4060, Cell Signaling Technology), 
anti-phospho-MEK (#9154, Cell Signaling Technology), 
anti-phospho-ERK (#4370, Cell Signaling Technology), 
anti-p21Cip1 (ab2961; Abcam), anti-p27Kip1 (ab7961; 
Abcam), anti-p16INK4A (10883-1-AP; Proteintech), anti-
HP1γ (ab10480, Abcam), anti-DcR2 (ab2019; Abcam), 
and anti-GAPDH (#2118; Cell Signaling Technology). 
Anti-rabbit IgG–HRP (Sigma-Aldrich) was used as 
the secondary antibody. Bands were detected using 
the enhanced chemiluminescence (ECL) Western blot 
detection system (Amersham Pharmacia Biotech, 
Piscataway, NJ, USA).
Senescence-associated β-galactosidase (SA-β-gal) 
assay
Frozen tissues embedded in OCT compound were 
sectioned into 6 μm slices. Sections were immediately 
immersed in a fixative solution (2% formaldehyde 
and 0.2% glutaraldehyde in PBS) for 15 min at room 
temperature. Following fixation, sections were stained 
with β-gal staining solution following the manufacturer’s 
instructions (#9860; Senescence β-galactosidase staining 
kit; Cell Signaling Technology). After overnight staining, 
the β-gal-stained sections were analyzed using a 
microscope (Eclipse Ti; Nikon).
Statistical analysis
The liver weight/body weight ratio (LW/BW) data 
were expressed as the means ± SD with sample sizes n = 5 
or larger. Statistical analyses of these data were conducted 
via an unpaired parametric Student’s t-test. Significant 
differences between two groups were denoted by asterisks 
(*, p < 0.05; **, p < 0.01; ***, p < 0.001). Kaplan–Meier 
survival data were evaluated using a log-rank test.
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